A generic concept has been proposed for COVID-19 protein subunit vaccines, which is the vaccine technology platform that is used by the COVID-19 Novavax vaccine product.
The proposed concept is as follows:
FSN: Vaccine product containing* only* Severe acute respiratory syndrome coronavirus 2 recombinant protein antigen
Semantic tag: medicinal product
PT: Canadian Preferred term could remain as proposed, COVID-19 protein subunit vaccine
Please let the CVC team know if you have any feedback on this approach. We will also add this to the agenda for review and discussion at the next CVC monthly working group meeting.
Improving the quality of patient care through the effective sharing of clinical information among health care organizations, clinicians and their patients.
Request for feedback: Proposed generic concept for COVID-19 protein subunit vaccines
Print
Email
Twitter